ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025
Bi-plane trans-rectal ultrasound (BTRUS) guided prostate perineal template based high dose rate interstitial brachytherapy (HDRIBT) for vaginal vault recurrence.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is limited evidence on the optimal management of vaginal vault recurrence (VVR) in patients with gynecological cancers. Real time bi-plane trans-rectal ultrasound (BTRUS) guidance with prostate perineal template with grid (PPTG) can ensure optimal placement of brachytherapy (BT) applicators for conformal high dose rate interstitial brachytherapy (HDRIBT) dose delivery. Materials and methods: The clinical outcome and HDRIBT dosimetric data of six patients with histologically confirmed recurrent or persistent carcinoma of the endometrium (3) and cervix (3) who underwent definitive PPTG based BTRUS-HDRIBT between 2019 and 2023 were retrospectively analysed. The local control (LC) and progression free survival (PFS) for five out of six patients with VVR were analysed by the Kaplan-Meier method using RStudio ver.2023.12.0+369 software. Dose volume uniformity index (DVUI) and dose volume conformity index (DVCI) were used to assess the HDRIBT plan quality. Results: The prescribed dose (PD) was 6 to 10 Gy. The two year LC rate and PFS for five patients are 100% [95% confidence interval (CI): 100%, 100%] and 80% (95% CI: 52%, 100%) respectively. Optimal mean DVUI (range 0.74-0.98) and mean DVCI (1.00) was achieved. At median follow up of 19 months, 3 patients are alive and free of disease. Most common toxicity is grade 1 hematuria. Conclusion: PPTG based BTRUS-HDRIBT for VVR allows real time tumor visualization for optimal applicator insertion to deliver highly conformal tumoricidal dose and maximize LC rate. Radiation oncologists dealing with prostate HDRIBT already possess this skill and this "dying art" can be readily transferable to female genital tract tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.